There are 3 IL-1 inhibitors on the market associated with the ligand/receptor signaling interaction, anakinra (Kineret; Amgen/Biovitrum), canakinumab (Ilaris; Novartis) and rilonacept (Arcalyst; Regeneron). Anakinra and rilonacept inhibits the effect of IL-1alpha as well as those of beta. As I understand it, diacerein/rhein prevents, the formation of IL-1beta and not the receptors.
My bad on both counts - and should have been more careful. But suggest it doesn't change the point of my post. The diacerein data is supportive of meaningful efficacy in OA - but not hugely so for the reasons I gave originally.
Market Data 
Markets 
AI
